Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Oncology Patients Receiving Chemotherapy 1Lymphoma, Non-Hodgkin 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × ocrelizumab × Clear all
NCT04189588 2023-10-06

versus

TerSera Therapeutics LLC

Phase 2 Completed
34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT02723071 2016-03-30

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Hoffmann-La Roche

Phase 1/2 Completed
48 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡